Summary (tl;dr)

Former President Donald Trump has signed an executive order to accelerate federal research into and access to psychedelic drugs, including ibogaine, specifically targeting conditions like PTSD and addiction, by reducing regulatory hurdles and providing significant research funding.

Essential Background

Ibogaine is a naturally occurring psychedelic compound derived from the Tabernanthe iboga shrub, native to Africa, and has been traditionally used in ceremonial practices. It is believed to help treat depression, anxiety, addiction, and post-traumatic stress disorder (PTSD), with some claiming it can interrupt opioid addiction and withdrawal. Despite its potential, ibogaine is classified as a Schedule I controlled substance in the United States, indicating it has no currently accepted medical use and a high potential for abuse, which severely limits its therapeutic use and research within the country. Consequently, many Americans seeking ibogaine treatment travel to countries where it is legal, such as Mexico. For years, advocates, including military veterans and conservative lawmakers, have pushed for greater access and research into psychedelics like ibogaine, with states such as Texas already committing funds for ibogaine research.

The Full Story

On April 18, 2026, former President Donald Trump signed an executive order aimed at accelerating research into and access to psychedelic drugs, including ibogaine. The order directs various U.S. government branches to expand research through measures like allocating match-funding via the Advanced Research Projects Agency for Health (ARPA-H) and reducing bureaucratic obstacles for conducting studies. Specifically, it calls for $50 million in federal match-funding for states investing in psychedelic studies, which is expected to directly benefit Texas's existing ibogaine research program. Concurrently, Food and Drug Administration (FDA) Commissioner Marty Makary announced investigational new drug (IND) clearance for ibogaine, allowing clinical trials to commence in the U.S. The executive order also streamlines the FDA's new drug application (NDA) review process, with the potential to cut approval times from months to weeks for certain psychedelics that receive National Priority Vouchers. This action follows discussions championed by Health Secretary Robert F. Kennedy Jr. and public advocacy from figures like conservative podcaster Joe Rogan, who has discussed ibogaine's potential and reportedly texted Trump about it. Joe Rogan was also present at the signing ceremony.

Why It Matters

This executive order marks a significant shift in federal policy regarding psychedelic substances, potentially signaling an end to decades of strict prohibition on medical research and access, which originated with the "war on drugs." It paves the way for increased federal funding and accelerated scientific study into ibogaine and other psychedelics, offering hope for new treatments for debilitating mental health conditions, particularly PTSD and addiction, which deeply affect populations like military veterans. However, some critics have raised concerns that rapidly expanding access could lead to unintended public health consequences due to potential safety risks associated with substances like ibogaine, which has been linked to heart problems in certain cases. The order also underscores a growing bipartisan interest in exploring alternative treatments for the mental health crisis, suggesting a potential for broader psychedelic policy reforms at both federal and state levels.

Geographic Location

• White House, Washington, D.C., District of Columbia, United States (signing of executive order)
• Texas, United States (state funding for ibogaine research)
• Mexico (location of unregulated ibogaine clinics used by Americans)